Cell Biochemistry and Biophysics

, Volume 62, Issue 1, pp 55–58 | Cite as

Treatment with Huperzine A Improves Cognition in Vascular Dementia Patients

  • Zhi-Qiang Xu
  • Xiao-Min Liang
  • Juan-Wu
  • Yuan-Feng Zhang
  • Chun-Xia Zhu
  • Xiao-Jiang Jiang
Original Paper

Abstract

In the present study, we tested the efficacy and safety of Huperzine A in treatment of mild to moderate vascular dementia (VaD). This was a randomized, double-blinded, placebo-controlled study with 78 patients with mild to moderate VaD. The participants were randomized to receive either vitamin C (100-mg bid) as placebo (n = 39) or Huperzine A (0.1-mg bid) (n = 39) for 12 consecutive weeks. The mini-mental state examination (MMSE), clinical dementia rating (CDR), and activities of daily living (ADL) scores were used for the assessment of cognition. The assessments were made prior to treatment, and 4, 8, and 12 weeks of the treatment. The adverse effects of the treatment were also recorded. After 12 weeks of treatment, the MMSE, CDR, and ADL scores significantly improved in the Huperzine A group (P < 0.01 for all comparisons), whereas the placebo group did not show any such improvement (P > 0.05 for all comparisons). No serious adverse events were recorded during the treatment. Conclusion: Huperzine A can significantly improve the cognitive function in patients with mild to moderate vascular dementia. Further, the medicament is safe.

Keywords

Huperzine A Vascular dementia Cognition Mini-mental state examination Clinical dementia rating Activities of daily living 

Notes

Acknowledgments

This study is supported by the Natural Science Foundation Project of CQ CSTC (2008BB5014) and the Scientific Research & Innovation Fund of the Third Military Medical University of China (2007XG063).

References

  1. 1.
    Roman, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., et al. (1993). Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 43, 250–260.PubMedGoogle Scholar
  2. 2.
    Dhoat, S., Ali, K., Bulpitt, C. J., & Rajkumar, C. (2008). Vascular compliance is reduced in vascular dementia and not in Alzheimer’s disease. Age and Ageing, 37, 653–659.PubMedCrossRefGoogle Scholar
  3. 3.
    Zhou, H., Deng, J., Li, J., Wang, Y., Zhang, M., & He, H. (2003). Study of the relationship between cigarette smoking, alcohol drinking and cognitive impairment among elderly people in China. Age and Ageing, 32, 205–210.PubMedCrossRefGoogle Scholar
  4. 4.
    Roman, G. C. (2005). Cholinergic dysfunction in vascular dementia. Current Psychiatry Reports, 7, 18–26.PubMedCrossRefGoogle Scholar
  5. 5.
    Wang, J., Zhang, H. Y., & Tang, X. C. (2009). Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment. Acta Pharmacologica Sinica, 30, 879–888.PubMedCrossRefGoogle Scholar
  6. 6.
    Black, S., Roman, G. C., Geldmacher, D. S., Salloway, S., Hecker, J., Burns, A., et al. (2003). Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke, 34, 2323–2330.PubMedCrossRefGoogle Scholar
  7. 7.
    Liu, J. S., Zhu, Y. L., Yu, C. M., Zhou, Y. Z., Han, Y. Y., Wu, F. W., et al. (1986). The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity. Can J Chem, 64, 837–839.CrossRefGoogle Scholar
  8. 8.
    Li, Y. X., Zhang, R. Q., Li, C. R., & Jiang, X. H. (2007). Pharmacokinetics of huperzine A following oral administration to human volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 32, 183–187.PubMedCrossRefGoogle Scholar
  9. 9.
    Wang, B. S., Wang, H., Wei, Z. H., Song, Y. Y., Zhang, L., & Chen, H. Z. (2009). Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: An updated meta-analysis. Journal of Neural Transmission, 116, 457–465.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhang, H. Y., Zheng, C. Y., Yan, H., Wang, Z. F., Tang, L. L., Gao, X., et al. (2008). Potential therapeutic targets of huperzine A for Alzheimer’s disease and vascular dementia. Chemico-Biological Interactions, 175, 396–402.PubMedCrossRefGoogle Scholar
  11. 11.
    Wang, J., Zhang, H. Y., & Tang, X. C. (2010). Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. Journal of Neuroscience Research, 88, 807–815.PubMedGoogle Scholar
  12. 12.
    Park, P., Schachter, S., & Yaksh, T. (2010). Intrathecal huperzine A increases thermal escape latency and decreases flinching behavior in the formalin test in rats. Neuroscience Letters, 470, 6–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Xu, Z., Zheng, H., Law, S. L., Dong, S. D., Han, Y., & Xue, H. (2006). Effects of a memory enhancing peptide on cognitive abilities of brain-lesioned mice: Additivity with huperzine A and relative potency to tacrine. Journal of Peptide Science, 12, 72–78.PubMedCrossRefGoogle Scholar
  14. 14.
    Wang, Q., & Chen, G. (2009). Pharmacokinetic behavior of huperzine A in plasma and cerebrospinal fluid after intranasal administration in rats. Biopharmaceutics and Drug Disposition, 30, 551–555.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Zhi-Qiang Xu
    • 1
  • Xiao-Min Liang
    • 1
  • Juan-Wu
    • 1
  • Yuan-Feng Zhang
    • 1
  • Chun-Xia Zhu
    • 1
  • Xiao-Jiang Jiang
    • 1
  1. 1.Department of Neurology, Research Institute of SurgeryDaping Hospital, Third Military Medical UniversityChongqingChina

Personalised recommendations